EpiVario Inc. Press Releases

• Published on October 29, 2024 - 15:00 GMT

  

  EpiVario Announces Issuance of Seminal Patents Covering ACSS2 Inhibitors and their Use in Substance Use Disorders

  USPTO and Japan Patent Office issue patents for novel compounds inhibiting ACSS2 and their use for treating or preventing a memory-related disorders PHILADELPHIA, PA, UNITED STATES, October 29, 2024 /⁨EINPresswire.com⁩/ -- EpiVario, Inc., a biotech …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on October 15, 2024 - 12:00 GMT

  

  EpiVario Announces Appointment of Chris Cashman to the Board of Directors

  Company welcomes esteemed life sciences executive and community leader as current board member moves to observer status PHILADELPHIA, PA, UNITED STATES, October 15, 2024 /⁨EINPresswire.com⁩/ -- EpiVario, Inc., a biotech company at the forefront of …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on July 23, 2024 - 13:00 GMT

  

  EpiVario CEO Thomas Kim Accepted into Prestigious Babson SUD Sprint Program

  Mr. Kim will join leading substance use solution innovators to collaborate on approaches to treat leading societal problem PHILADELPHIA, PA, USA, July 23, 2024 /⁨EINPresswire.com⁩/ -- EpiVario is proud to announce that CEO Thomas Kim has been selected to …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on June 11, 2024 - 13:00 GMT

  

  EpiVario Awarded NIH Grant to Advance Research in Treatments for Cocaine Use Disorder

  Company to receive $295,000 in research funding from the National Institute on Drug Abuse PHILADELPHIA, PA, USA, June 11, 2024 /⁨EINPresswire.com⁩/ -- EpiVario, Inc., a biotech company at the forefront of developing novel therapeutics for memory-related …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on May 21, 2024 - 13:00 GMT

  

  EpiVario Licenses Portfolio of ACSS2 Inhibitor Compounds to ReEngage Therapeutics for Cancer Indications

  Expands therapeutic reach of novel class with potential in both neuroscience and oncology PHILADELPHIA, PA, UNITED STATES, May 21, 2024 /⁨EINPresswire.com⁩/ -- EpiVario Inc., a biotech company pioneering neuroepigenetics to treat addiction disorders, …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...